[go: up one dir, main page]

US20070054965A1 - AMPK activating agent - Google Patents

AMPK activating agent Download PDF

Info

Publication number
US20070054965A1
US20070054965A1 US11/480,504 US48050406A US2007054965A1 US 20070054965 A1 US20070054965 A1 US 20070054965A1 US 48050406 A US48050406 A US 48050406A US 2007054965 A1 US2007054965 A1 US 2007054965A1
Authority
US
United States
Prior art keywords
nootkatone
agent
exercise
ampk
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/480,504
Inventor
Takatoshi Murase
Yoshihiko Minegishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2005257047A external-priority patent/JP4745764B2/en
Priority claimed from JP2005338405A external-priority patent/JP4719556B2/en
Application filed by Kao Corp filed Critical Kao Corp
Assigned to KAO CORPORATION reassignment KAO CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MINEGISHI, YOSHIHIKO, MURASE, TAKATOSHI
Publication of US20070054965A1 publication Critical patent/US20070054965A1/en
Priority to US13/008,086 priority Critical patent/US8829057B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to an AMPK (AMP-activated protein kinase) activating agent.
  • AMPK AMP-activated protein kinase
  • AMPK AMP-activated protein kinase
  • AMPK AMP-activated protein kinase
  • AMPK is known to promote energy consumption through its activation.
  • recent research has suggested that AMPK is not only regulated by intracellular energy levels but also activated by muscular activity, leptin (Nature, Vol.
  • adipocyte-derived hormones such as adiponectin (Nature, Vol. 423, p. 762-769, 2003), metformin, a therapeutic drug for diabetes, (J. Clin. Invest., Vol. 108, p. 1167-1174, 2001), and so on, and acts as an intracellular mediator of fatty acid oxidation or glucose utilization promoting action induced by them.
  • AMPK is known to activate, through the control of acetyl-CoA carboxylase (ACC) activity, carnitine palmitoyltransferase (CPT-1) that transfers long-chain fatty acid to mitochondria, thereby promoting fatty acid oxidation.
  • ACC acetyl-CoA carboxylase
  • CPT-1 carnitine palmitoyltransferase
  • CPT-1 is strongly inhibited by malonyl-CoA, an ACC product, while AMPK is considered to phosphorylate Ser79 of the ACC, thereby suppressing the ACC activity.
  • drugs that activate AMPK are useful for preventing and treating lifestyle-related diseases including obesity and diabetes by promoting fatty acid oxidation and increasing energy expenditures or are useful for removing lack of exercise by exerting effect similar to that of exercise.
  • AICAR 5-aminoimidazole-4-carboxamide
  • Possible one means for solving these problems is to routinely ingest food ingredients having endurance-enhancing or antifatigue action.
  • the present inventors have found endurance-enhancing effect provided by the consumption of catechin (JP-A-2005-89384).
  • Additional examples of the ingredients previously reported to have endurance-enhancing effect include a hawthorn extract (JP-A-08-47381), a Fomes japonicus component (JP-A-05-123135), and proanthocyanidin and lycopene (JP-A-2005-334022).
  • examples of the ingredients having antifatigue effect include a composition containing coenzyme Q10 and carnitine (JP-A-2005-97161) and a glutamine peptide (JP-A-2005-97162).
  • Nootkatone is 4,4a,5,6,7,8-hexahydro-6-isopropenyl-4,4a-dimethyl-2(3H)-naphthalenone or sesquiterpene ketone, is a substance that is present in grapefruit peels and the like, and has received much attention as a flavor because of its characteristic flavor and taste of grapefruit (“Latest Encyclopedia of Perfume and Flavor” edited by Soichi Arai, 1st ed., Asakura Publishing, May 10, 2000, p. 112, p. 254). However, its physiological activity has hardly been reported so far.
  • grapefruits a perfume composition containing grapefruit oil (essential oil) has been reported to activate the sympathetic nervous system, thereby exhibiting antiobesity action (JP-A-2002-193824), and an external skin preparation containing grapefruit oil (JP-A-2005-47935) has also been reported.
  • the antiobesity action of nootkatone has never been known.
  • the influence of nootkatone on exercise capacity including endurance or on fatigue has never been known so far.
  • the present invention relates to the following inventions:
  • (11) a method for preventing, treating and/or improving lifestyle-related disease, including administering nootkatone in an effective amount;
  • the present invention relates to provision of AMPK activating agent, endurance enhancing agent, and antifatigue agent, which have rich history of use in foods, high safety, readily available, and high workability, a method of activating AMPK, and a method of preventing, treating and/or ameliorating a life-style-related disease.
  • nootkatone has AMPK-activating action and is useful by its consumption in the prevention, treatment, and improvement of life-style-related disease such as obesity, hyperlipidemia, diabetes, and arteriosclerosis, in the removal of lack of exercise, and in endurance enhancement and antifatigue.
  • the present invention provides AMPK activating agent, endurance enhancing agent, and antifatigue agent, each of which contains nootkatone as an active agent.
  • the present invention provides a method of activating AMPK characterized by administering nootkatone in an effective amount, and a method of preventing, treating and/or ameliorating a life-style-related disease characterized by administering nootkatone in an effective amount.
  • lipid metabolism activating agent induce activation of energy metabolism such as lipid metabolism and glucose metabolism and are excellent in safety
  • they are useful in the prevention, treatment, and/or improvement of lifestyle-related diseases such as obesity, hyperlipidemia, diabetes, and arteriosclerosis, and are useful in the removal of lack of exercise and further in endurance enhancement and/or antifatigue for broadly defined exercise including exercise, routine bodily movements, and working by exhibiting effect similar to exercise.
  • nootkatone refers to 4,4a,5,6,7,8-hexahydro-6-isopropenyl-4,4a-dimethyl-2(3H)-naphthalenone or sesquiterpene ketone.
  • Nootkatone includes 8 types of optical isomers.
  • (+)-nootkatone represented by the following structural formula (I) is used:
  • Nootkatone used in the present invention can be produced by organic chemical synthesis, synthesis with microorganisms, and the like, known in the art, and can be obtained by the methods described in, for example JP-A-2004-123561 and JP-A-2003-250591 and JP-A-1999-501052.
  • nootkatone used in the present invention can be extracted from natural products containing nootkatone by methods known in the art.
  • the extraction can be performed by a technique appropriately combining an extraction using water, hot water, alcohol water, organic solvents, or the like, and a purification or distillation by high-performance liquid chromatography, column chromatography, or the like.
  • the natural products containing nootkatone include grapefruits.
  • nootkatone is extracted from grapefruits, for example a fruit, peel, oil, concentrated juice, or squeezed juice residue of a grapefruit can be used as a raw material thereof.
  • nootkatone obtained by synthesis or extraction is converted for use to a high-purity product by removing impurities by single- or multiple-step purification or the like, or may also be any semi-purified product that achieves the advantages of the present invention.
  • Nootkatone of the present invention has a strong AMPK-activating action in muscle cells, as shown in Examples below. Therefore, nootkatone can be used as an AMPK activating agent.
  • the AMPK activation promotes lipid oxidation and energy consumption. Moreover, the AMPK activation increases glucose uptake via glucose transporters (GLUTs) and promotes glucose use.
  • GLUTs glucose transporters
  • nootkatone is useful as a lipid metabolism activating agent, antiobesity agent, antidiabetic agent, antiarteriosclerotic agent, antihyperlipidemic agent, endurance enhancing agent, antifatigue agent, and agent for preventing, treating, and/or improving lifestyle-related disease.
  • nootkatone improves a variety of symptoms partly caused by lack of exercise and is therefore useful as an exercise-substituting agent having effect similar to that of exercise.
  • Nootkatone is useful as an exercise-substituting agent intended for the prevention and improvement of body fat accumulation, fatty liver, and lifestyle-related diseases, particularly obesity and diabetes.
  • the lifestyle-related diseases of the present invention refers to obesity, hyperlipidemia, diabetes, arteriosclerosis, and the like.
  • endurance-enhancing and antifatigue effects refer to those for broadly defined exercise including exercise, routine bodily movements, and working.
  • the AMPK activating agent and so on of the present invention can be administered to humans and animals and can be ingested by mixing them into a variety of foods, drinks, pharmaceuticals, pet foods, and so on.
  • the agents of the present invention When used as food or drink, they can be processed as drink forms into drinks such as fruit juice drinks, carbonated drinks, tea-based drinks, dairy drinks, alcohol drinks, and soft drinks, and as food forms into foods such as jellied foods, a variety of snacks, baked goods, cake products, chocolate, gum, candy, and soups.
  • the agents of the present invention can be applied to functional foods and drinks, invalid diets, and foods for specified health use, which present concepts of physiological function such as prevention and/or improvement of lifestyle-related diseases (e.g., obesity, hyperlipidemia, diabetes, and arteriosclerosis), enhancement of physiological function (e.g., hyperglycemia, insulin resistance, and lipid metabolism promotion) and endurance, and prevention or improvement of fatigue.
  • lifestyle-related diseases e.g., obesity, hyperlipidemia, diabetes, and arteriosclerosis
  • enhancement of physiological function e.g., hyperglycemia, insulin resistance, and lipid metabolism promotion
  • endurance e.g., and prevention or improvement of fatigue.
  • the agents of the present invention are used as pharmaceutical drugs, they can be made into oral solid preparations such as tablets and granules and into oral liquid preparations such as internal-use liquid medicines and syrups.
  • nootkatone of the present invention can be supplemented appropriately with pharmaceutically acceptable carriers, for example excipients, if necessary, binders, disintegrants, lubricants, coloring agents, flavoring agents, and odor-improving agents, to produce tablets, coated tablets, granules, powders, capsules, and so on by routine methods.
  • pharmaceutically acceptable carriers for example excipients, if necessary, binders, disintegrants, lubricants, coloring agents, flavoring agents, and odor-improving agents, to produce tablets, coated tablets, granules, powders, capsules, and so on by routine methods.
  • nootkatone of the present invention can be supplemented with flavoring agents, buffers, stabilizers, and so onto produce internal-use liquid medicines, syrups, elixirs, and so on by routine methods.
  • the amount of nootkatone mixed into the food, drink, pharmaceutical drug, pet food, and so on differs depending on its usage pattern and is usually 0.0002 to 5% by mass, preferably 0.001 to 3% by mass, more preferably 0.02 to 2% by mass when nootkatone is used in the foods, drinks, and pet foods.
  • the amount of nootkatone used in a pharmaceutical drug for example an oral solid preparation such as tablets, granules, capsules or an oral liquid preparation such as internal-use liquid medicines and syrups is usually 0.01 to 95% by mass, preferably 0.1 to 95% by mass, more preferably 2 to 80% by mass.
  • the doses (effective intakes) of the AMPK activating agent, lipid metabolism activating agent, antiobesity agent, antidiabetic agent, antiarteriosclerotic agent, antihyperlipidemic agent, and exercise-substituting agent of the present invention are preferably 1 to 2000 mg/60 kg of body weight per day, more preferably 1 to 1000 mg/60 kg of body weight per day, even more preferably 2 to 1000 mg/60 kg of body weight per day, still even more preferably 2 to 700 mg/60 kg of body weight per day, yet still more preferably 5 to 500 mg/60 kg of body weight per day, in terms of the amount of nootkatone.
  • a muscle cell line (C2C12) was used to evaluate the AMPK-activating action of nootkatone according to the procedures below with AMPK ⁇ and AMPK ⁇ phosphorylation as indexes.
  • Cells of the murine muscle cell line (C2C12) were seeded onto a 25 cm 2 flask and cultured in DMEM (+10% FBS, +antimicrobial agent) at 37° C. for 1 to 2 days. When the cells became confluent, the culture solution was removed, and the cells were washed with PBS ( ⁇ ) and further cultured for 7 to 8 days in fresh DMEM (2% (V/V) horse serum), which was in turn replaced by a fresh culture solution every 2 to 3 days. The culture solution was then removed, and the cells were washed with PBS ( ⁇ ) and further cultured in fresh DMEM ( ⁇ FBS) for 1 day.
  • DMEM +10% FBS, +antimicrobial agent
  • the cells were cultured in DMEM ( ⁇ FBS) containing a predetermined concentration of nootkatone (obtained from Wako Pure Chemical Industries, Ltd.) for 60 minutes. After the culture solution was subsequently removed and the cells were washed with PBS ( ⁇ ), 200 ⁇ L of cell lysis solution (10 mmol/L Tris (pH 7.4), 50 mmol/L sodium chloride, 30 mmol/L sodium pyrophosphate, 0.5% (V/V) Triton X-100, protease inhibitor cocktail (SIGMA P2714), phosphatase inhibitor cocktail-1 (SIGMA P2850), phosphatase inhibitor cocktail-2 (SIGMA P5726)) was added and the cell lysis solution was collected with a cell scraper.
  • DMEM ⁇ FBS
  • nootkatone obtained from Wako Pure Chemical Industries, Ltd.
  • the collected cell lysis solution was well homogenized by passing it through a syringe with a 23G needle three times and then left on ice for 30 minutes.
  • the homogenate was centrifuged at 15000 r/min at 4° C. for 15 minutes, and the resulting supernatant protein was used in the measurement below.
  • the concentration of the supernatant protein was measured, and the protein concentrations were then adjusted among samples to constant concentrations.
  • SDS buffer 250 mmol/L Tris, 12.5% by mass of SDS, 20% by mass of glycerin
  • 2-mercaptoethanol and bromophenol blue were added to each of the samples.
  • the resulting mixtures were thermally denatured at 95° C. and rapidly cooled at 4° C. to prepare samples for electrophoresis.
  • Predetermined amounts (approximately 20 to 40 ⁇ g) of the samples for electrophoresis were subjected to SDS-PAGE (12% gel) and transferred to a membrane. Then, phospho-AMPK ⁇ and phospho-AMPK ⁇ were detected by using anti-phospho-AMPK ⁇ (Thr72) antibodies (manufactured by Cell Signaling Technology, Inc.) or anti-phospho-AMPK ⁇ (Ser108) antibodies (manufactured by Cell Signaling Technology, Inc.) as primary antibodies, anti-rabbit-HRP antibodies (manufactured by Amersham Biosciences) as secondary antibodies, and Phototope-HRP Western Detection System (manufactured by Cell Signaling Technology, Inc.) as a detection reagent.
  • the degree of AMPK activation was indicated as a relative value to that of a control (sample-free group) defined as 100 by digitizing (pixelizing) detected band strength by image analysis (EDAS290 image analysis system; KODAK). TABLE 1 Nootkatone ( ⁇ mol/L) Control 50 100 150 Phospho- 100 402 952 1077 AMPK ⁇ Phospho- 100 241 314 358 AMPK ⁇
  • nootkatone has a strong AMPK-activating action in the muscle cells.
  • mice Seven-week-old C57BL/6 male mice were divided into 3 groups each containing 10 mice and raised with each diet of the composition described in Table 2. TABLE 2 (%) Group 1 Group 2 Group 3 Plant oil 5 25 25 Lard 0 5 5 Sucrose 0 13 13 Casein 20 20 20 Potato starch 66.5 28.5 28 Vitamin 1 1 1 Mineral 3.5 3.5 3.5 Cellulose 4 4 4 Nootkatone 0 0 0.5
  • Nootkatone of the present invention had excellent inhibitory effect on a rise in blood cholesterol level and was therefore considered to be effective for inhibiting arteriosclerosis.
  • Nootkatone of the present invention had excellent inhibitory effect on a rise in blood insulin level and was therefore considered to be effective for controlling hyperinsulinemia. Moreover, this result shows that nootkatone inhibits the onset of Type 2 diabetes with insulin resistance.
  • mice Seven-week-old Balb/c male mice were divided into 2 groups, to which a physiological saline (control) or nootkatone at 200 mg/kg of body weight was then orally administered for 10 consecutive days. Then, their livers and skeletal muscles (gastrocnemius muscle+soleus muscle) were collected. The livers and skeletal muscles were respectively homogenized in a buffer (250 mM sucrose, 1 mM EDTA in 10 mM HEPES (pH 7.2)), and the insoluble tissue residues were removed by centrifugation to obtain supernatants. The obtained supernatants were measured for protein levels. The protein levels were adjusted among samples to constant levels, and the samples were used in the measurement of lipid metabolism activity ( ⁇ -oxidation activity).
  • a physiological saline control
  • nootkatone at 200 mg/kg of body weight was then orally administered for 10 consecutive days. Then, their livers and skeletal muscles (gastrocnemius muscle+soleus muscle) were collected. The livers
  • a 100- ⁇ g aliquot of the supernatant protein was reacted at 37° C. for 20 minutes with 0.1 ⁇ Ci [ 14 C]-palmitic acid in a buffer (50 mM Tris-HCl (pH 8.0), 40 mM NaCl, 2 mM KCl, 2 mM MgCl 2 , 1 mM DTT, 5 mM ATP, 0.2 mM L-carnitine, 0.2 mM NAD, 0.06 mM FAD, 0.12 mM CoA, 3 mM ⁇ -cyclodextrin) at the final volume of 200 ⁇ L.
  • a buffer 50 mM Tris-HCl (pH 8.0), 40 mM NaCl, 2 mM KCl, 2 mM MgCl 2 , 1 mM DTT, 5 mM ATP, 0.2 mM L-carnitine, 0.2 mM NAD, 0.06 mM FAD, 0.12
  • the reaction was terminated with 200 ⁇ L of 0.6 N perchloric acid, and the unreacted [ 14 C]-palmitic acid was removed 3 times with 1 mL hexane. Lipid-degrading activity was measured by measuring radioactivity of the aqueous layer.
  • the measurement result is shown in Table 5.
  • the degree of the lipid-degrading activity was indicated as a relative value to that of the control defined as 100.
  • the lipid-degrading activity ( ⁇ -oxidation activity) of the liver and skeletal muscle remarkably increased in the mice fed with nootkatone.
  • nootkatone was shown to be effective for activating lipid metabolism.
  • Nootkatone also improved a variety of the symptoms partly caused by lack of exercise via its AMPK-activating action and was therefore shown to be useful as an exercise-substituting agent having effect similar to that of exercise, particularly an exercise-substituting agent intended for the prevention and improvement of obesity, body fat accumulation, diabetes, fatty liver, lifestyle-related disease, and the like.
  • Nootkatone used was a product of Avocado.
  • the endurance-enhancing and antifatigue effects were evaluated according to the measurement method of maximum swimming time of mice (Reference: Am J Physiol Regul Integr Comp Physiol, Vol. 288, R708-R715, 2005) in a current water pool.
  • the experimental pool used was a clear acrylic pool (90 cm long ⁇ 45 cm wide ⁇ 45 cm deep) filled to a depth of 38 cm with water maintained at 34° C. with a heater.
  • the current in the pool was generated with a pump (C-P60H, manufactured by Hitachi), and the current speed was adjusted by connecting Water flowmeter (Tofco) to the pump and opening and closing a valve.
  • the current speed was measured with a digital current meter (SV-101-25S, Sankou Seimitsu Kogyo).
  • mice were 5-week-old Balb/c male mice (Charles River Laboratories, Inc.). The mice were preliminarily raised for 1 week under a constant raising environment (23 ⁇ 2° C., light period: 7 a.m. to 7 p.m.) and acclimated. In subsequent 1-week training, the mice were accustomed to swimming exercise three times a week (subjected to swimming exercise for 30 minutes at a current speed of 5 L/min on the first day, and for 30 minutes at a current speed of 6 L/min on the third and fifth days).
  • the maximum swimming time of each of the individuals fasted for 2 hours was measured twice at a current speed of 7 L/min (maximum swimming time was set to the point in time when the mouse failed to rise to the surface of the water to breathe and was rescued).
  • the mice were divided into 2 groups, a test diet group and a control diet group, each containing 8 mice, to prevent a difference in maximum swimming time between the groups. Diets prepared in the formulation composition shown in Table 8 were used to raise the mice for 10 weeks. During this period, the measurement of maximum swimming time (7 L/min) and training (6 L/min, 30 minutes) were performed once every week. The maximum swimming times of the mice on the 10th week of raising are shown in Table 7.
  • Control diet Test diet Lipid (%) 10 10 10 Casein (%) 20 20 Potato starch (%) 55.5 55.3 Cellulose (%) 8.1 8.1 Vitamin (%) 2.2 2.2 Methionine (%) 0.2 0.2 Mineral (%) 4 4 Nootkatone (%) 0 0.2 Total (%) 100 100
  • compositions 300 mg were encapsulated into an encapsulating agent.
  • TABLE 8 Nootkatone 50% by weight Corn starch 20 Cellulose 18 Tocopherol 2 Lactose 10 (2) Tablet for Prevention or Improvement of Lifestyle-Related Diseases
  • compositions described below were mixed to produce a fruit juice drink. TABLE 11 Nootkatone 100 mg Grapefruit juice 500 mL (5) Drink for Prevention or Improvement of Obesity or Lifestyle-Related Disease
  • compositions described below were mixed to produce a fruit juice drink.
  • compositions described below were mixed to produce a sports drink.
  • TABLE 14 Water 500 mL Nootkatone 60 mg Fructose 3 g Glucose 2 g Vitamin C 500 mg Citric acid 100 mg Sodium citrate 2 g Flavor Certain quantity Malic acid 200 mg (8) Exercise-Substituting Functional Drink
  • compositions described below were mixed to produce a drink. TABLE 19 Water 350 mL Nootkatone 5 mg Fructose 3 g Glucose 2 g Vitamin C 750 mg Citric acid 100 mg Sodium citrate 1.5 g Flavor Certain quantity Malic acid 150 mg (13) Drink for Prevention or Improvement of Obesity or Lifestyle-Related Diseases
  • compositions described below were mixed to produce a fruit juice drink.
  • TABLE 20 Nootkatone 4 mg Vitamin C 300 mg Orange juice 300 mL Water 200 mL Flavor Certain quantity Isomerized sugar 5 g (14) Tablet for Prevention or Improvement of Lifestyle-Related Diseases
  • compositions described below were mixed to produce a fruit juice drink.
  • TABLE 22 Nootkatone 5 mg Vitamin C 300 mg Grapefruit juice 400 mL Water 100 mL Flavor Certain quantity Glucose 2 g (16) Capsule for Endurance Enhancement or Antifatigue
  • compositions 300 mg were encapsulated into an encapsulating agent. TABLE 23 Nootkatone 5% by mass Vitamin C 20 Cellulose 10 Corn starch 40 Tocopherol 2 Lactose 23 (17) Tablet for Endurance Enhancement or Antifatigue
  • compositions described below were mixed to produce a drink for endurance enhancement or antifatigue.
  • TABLE 27 Water 500 mL Nootkatone 10 mg Fructose 3 g Glucose 2 g Vitamin C 500 mg Sodium citrate 2 g Malic acid 100 mg Caffeine 50 mg Flavor Certain quantity (21) Capsule for Endurance Enhancement or Antifatigue
  • compositions 300 mg were encapsulated into an encapsulating agent. TABLE 28 Nootkatone 10% by mass Vitamin C 20 Cellulose 10 Corn starch 45 Tocopherol 2 Lactose 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to provision of AMPK activating agent, endurance enhancing agent, and antifatigue agent, which have rich history of use in foods, high safety, readily available, and high workability, a method of activating AMPK, and a method of preventing, treating and/or ameliorating a life-style-related disease. The present invention provides AMPK activating agent, endurance enhancing agent, and antifatigue agent, each of which contains nootkatone as an active agent. The present invention provides a method of activating AMPK characterized by administering nootkatone in an effective amount, and a method of preventing, treating and/or ameliorating a life-style-related disease characterized by administering nootkatone in an effective amount.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to an AMPK (AMP-activated protein kinase) activating agent.
  • 2. Background of the Invention
  • In recent years, population with obesity has increased, and so-called lifestyle-related diseases such as diabetes associated with obesity have become grave social problems. Obesity is generated as a result of energy excess in which energy intakes exceed energy consumption. Thus, the bases for prevention and improvement of obesity and diabetes developed therewith are, for example, a decrease in energy intakes by decreasing meal size or an increase in energy consumption by exercise.
  • However, in the modern society, lipid intakes have increased due to the westernization of eating habits, while the amount of exercise and energy consumption have decreased due to the proliferation of automobiles, and soon. As a result, so-called lifestyle-related diseases such as diabetes have been growing in number with an increase in population with obesity and become grave social problems. Exercise has widely been acknowledged to be effective for preventing and improving a variety of lifestyle-related diseases including obesity and diabetes by promoting energy metabolism. However, it is quite difficult to perform routine exercise in real life. Therefore, it is useful, if possible, to provide some method other than exercise, which has effect similar to that brought by exercise, or to effectively exploit the action of the limited exercise. Namely, the development of exercise-substituting means that exhibits effect similar to that of exercise despite that no actual exercise has been demanded.
  • For example, many compounds and extracts such as a soybean extract (JP-A-2003-286180), cyanidin 3-glucoside (JP-A-2003-252766), sugar cane polyphenol (JP-A-2003-137803), D-cysteinolic acid (JP-A-2003-104879), and conjugated trienoic acid-based oil and fat (JP-A-2002-186424) have heretofore been founded as substances preventing or improving obesity. However, most of their mechanisms of action on the improvement of obesity remain unknown. Moreover, their safety is not sufficiently confirmed owing to poor history of use in foods. Thus, the fact is that their usefulness is not sufficiently established.
  • On the other hand, as studies on energy metabolism and on mechanisms of obesity and diabetes onset have proceeded, AMPK has been shown to play a pivotal role therein (Molecular Medicine, Vol. 39, No. 4, p. 398-407, 2002). AMPK (AMP-activated protein kinase) is a ubiquitous protein in living bodies present in the muscles, liver and the like, and is known to be a protein whose activity is elevated under such circumstances that intracellular ATP levels are decreased, thereby promoting metabolism and ATP synthesis (“metabolic sensor”). Namely, AMPK is known to promote energy consumption through its activation. However, recent research has suggested that AMPK is not only regulated by intracellular energy levels but also activated by muscular activity, leptin (Nature, Vol. 415, p. 339-343, 2002), adipocyte-derived hormones such as adiponectin (Nature, Vol. 423, p. 762-769, 2003), metformin, a therapeutic drug for diabetes, (J. Clin. Invest., Vol. 108, p. 1167-1174, 2001), and so on, and acts as an intracellular mediator of fatty acid oxidation or glucose utilization promoting action induced by them. For example, AMPK is known to activate, through the control of acetyl-CoA carboxylase (ACC) activity, carnitine palmitoyltransferase (CPT-1) that transfers long-chain fatty acid to mitochondria, thereby promoting fatty acid oxidation. Namely, CPT-1 is strongly inhibited by malonyl-CoA, an ACC product, while AMPK is considered to phosphorylate Ser79 of the ACC, thereby suppressing the ACC activity. This suggests that drugs that activate AMPK are useful for preventing and treating lifestyle-related diseases including obesity and diabetes by promoting fatty acid oxidation and increasing energy expenditures or are useful for removing lack of exercise by exerting effect similar to that of exercise.
  • In addition to leptin, adiponectin, and metformin described above, AICAR (5-aminoimidazole-4-carboxamide) has previously been known as a compound that activates AMPK. However, easily available raw materials with rich history of use in foods, high safety, and excellent workability were very few until now.
  • In recent years, reduced endurance attributed to lack of exercise has been a problem along with the rapid aging of the population, the sophistication of transportation systems, and the progression of information/communication technology. Endurance is essential to not only athletic exercise but also all routine bodily movements including working, walking, and standing. Thus, endurance is exceedingly important for living a meaningful and healthy daily life. Exercise is said to be appropriate for enhancing endurance. However, the fact is that many persons cannot make enough time for exercise due to busyness or can not do exercise due to physical problems even if they want to do so.
  • Possible one means for solving these problems is to routinely ingest food ingredients having endurance-enhancing or antifatigue action. For example, the present inventors have found endurance-enhancing effect provided by the consumption of catechin (JP-A-2005-89384). Additional examples of the ingredients previously reported to have endurance-enhancing effect include a hawthorn extract (JP-A-08-47381), a Fomes japonicus component (JP-A-05-123135), and proanthocyanidin and lycopene (JP-A-2005-334022). Moreover, examples of the ingredients having antifatigue effect include a composition containing coenzyme Q10 and carnitine (JP-A-2005-97161) and a glutamine peptide (JP-A-2005-97162).
  • Nootkatone is 4,4a,5,6,7,8-hexahydro-6-isopropenyl-4,4a-dimethyl-2(3H)-naphthalenone or sesquiterpene ketone, is a substance that is present in grapefruit peels and the like, and has received much attention as a flavor because of its characteristic flavor and taste of grapefruit (“Latest Encyclopedia of Perfume and Flavor” edited by Soichi Arai, 1st ed., Asakura Publishing, May 10, 2000, p. 112, p. 254). However, its physiological activity has hardly been reported so far. Regarding grapefruits, a perfume composition containing grapefruit oil (essential oil) has been reported to activate the sympathetic nervous system, thereby exhibiting antiobesity action (JP-A-2002-193824), and an external skin preparation containing grapefruit oil (JP-A-2005-47935) has also been reported. The antiobesity action of nootkatone has never been known. Moreover, the influence of nootkatone on exercise capacity including endurance or on fatigue has never been known so far.
    • SUMMARY OF THE INVENTION
  • The present invention relates to the following inventions:
  • (1) an AMPK activating agent containing nootkatone as an active ingredient;
  • (2) a lipid metabolism activating agent containing nootkatone as an active ingredient;
  • (3) an antiobesity agent containing nootkatone as an active ingredient;
  • (4) an antidiabetic agent containing nootkatone as an active ingredient;
  • (5) an antiarteriosclerotic agent containing nootkatone as an active ingredient;
  • (6) an antihyperlipidemic agent containing nootkatone as an active ingredient;
  • (7) an exercise-substituting agent containing nootkatoneas an active ingredient;
  • (8) an endurance enhancing agent containing nootkatone as an active ingredient;
  • (9) an antifatigue agent containing nootkatone as an active ingredient;
  • (10) a method for activating AMPK including administering nootkatone in an effective amount;
  • (11) a method for preventing, treating and/or improving lifestyle-related disease, including administering nootkatone in an effective amount;
  • (12) a method for substituting exercise including administering nootkatone in an effective amount; and
  • (13) a method for enhancing endurance and/or for removing fatigue including administering nootkatone in an effective amount.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to provision of AMPK activating agent, endurance enhancing agent, and antifatigue agent, which have rich history of use in foods, high safety, readily available, and high workability, a method of activating AMPK, and a method of preventing, treating and/or ameliorating a life-style-related disease.
  • The present inventors have explored natural product materials with rich history of use in foods and have consequently found that nootkatone has AMPK-activating action and is useful by its consumption in the prevention, treatment, and improvement of life-style-related disease such as obesity, hyperlipidemia, diabetes, and arteriosclerosis, in the removal of lack of exercise, and in endurance enhancement and antifatigue.
  • The present invention provides AMPK activating agent, endurance enhancing agent, and antifatigue agent, each of which contains nootkatone as an active agent.
  • The present invention provides a method of activating AMPK characterized by administering nootkatone in an effective amount, and a method of preventing, treating and/or ameliorating a life-style-related disease characterized by administering nootkatone in an effective amount.
  • Because a lipid metabolism activating agent, antiobesity agent, antidiabetic agent, antiarteriosclerotic agent, antihyperlipidemic agent, exercise-substituting agent, endurance enhancing agent, and antifatigue agent of the present invention induce activation of energy metabolism such as lipid metabolism and glucose metabolism and are excellent in safety, they are useful in the prevention, treatment, and/or improvement of lifestyle-related diseases such as obesity, hyperlipidemia, diabetes, and arteriosclerosis, and are useful in the removal of lack of exercise and further in endurance enhancement and/or antifatigue for broadly defined exercise including exercise, routine bodily movements, and working by exhibiting effect similar to exercise.
  • In the present invention, nootkatone refers to 4,4a,5,6,7,8-hexahydro-6-isopropenyl-4,4a-dimethyl-2(3H)-naphthalenone or sesquiterpene ketone. Nootkatone includes 8 types of optical isomers.
  • In the present invention, these isomers can be used alone or in combination. Preferably, (+)-nootkatone represented by the following structural formula (I) is used:
    Figure US20070054965A1-20070308-C00001
  • Nootkatone used in the present invention can be produced by organic chemical synthesis, synthesis with microorganisms, and the like, known in the art, and can be obtained by the methods described in, for example JP-A-2004-123561 and JP-A-2003-250591 and JP-A-1999-501052.
  • Alternatively, nootkatone used in the present invention can be extracted from natural products containing nootkatone by methods known in the art. In this context, the extraction can be performed by a technique appropriately combining an extraction using water, hot water, alcohol water, organic solvents, or the like, and a purification or distillation by high-performance liquid chromatography, column chromatography, or the like. Examples of the natural products containing nootkatone include grapefruits. When nootkatone is extracted from grapefruits, for example a fruit, peel, oil, concentrated juice, or squeezed juice residue of a grapefruit can be used as a raw material thereof.
  • Preferably, nootkatone obtained by synthesis or extraction is converted for use to a high-purity product by removing impurities by single- or multiple-step purification or the like, or may also be any semi-purified product that achieves the advantages of the present invention.
  • Nootkatone of the present invention has a strong AMPK-activating action in muscle cells, as shown in Examples below. Therefore, nootkatone can be used as an AMPK activating agent. The AMPK activation promotes lipid oxidation and energy consumption. Moreover, the AMPK activation increases glucose uptake via glucose transporters (GLUTs) and promotes glucose use. Thus, nootkatone is useful as a lipid metabolism activating agent, antiobesity agent, antidiabetic agent, antiarteriosclerotic agent, antihyperlipidemic agent, endurance enhancing agent, antifatigue agent, and agent for preventing, treating, and/or improving lifestyle-related disease.
  • Moreover, nootkatone improves a variety of symptoms partly caused by lack of exercise and is therefore useful as an exercise-substituting agent having effect similar to that of exercise. Nootkatone is useful as an exercise-substituting agent intended for the prevention and improvement of body fat accumulation, fatty liver, and lifestyle-related diseases, particularly obesity and diabetes.
  • In this context, the lifestyle-related diseases of the present invention refers to obesity, hyperlipidemia, diabetes, arteriosclerosis, and the like. Moreover, endurance-enhancing and antifatigue effects refer to those for broadly defined exercise including exercise, routine bodily movements, and working.
  • The AMPK activating agent and so on of the present invention can be administered to humans and animals and can be ingested by mixing them into a variety of foods, drinks, pharmaceuticals, pet foods, and so on.
  • When the agents of the present invention are used as food or drink, they can be processed as drink forms into drinks such as fruit juice drinks, carbonated drinks, tea-based drinks, dairy drinks, alcohol drinks, and soft drinks, and as food forms into foods such as jellied foods, a variety of snacks, baked goods, cake products, chocolate, gum, candy, and soups. In addition to general foods and drinks, the agents of the present invention can be applied to functional foods and drinks, invalid diets, and foods for specified health use, which present concepts of physiological function such as prevention and/or improvement of lifestyle-related diseases (e.g., obesity, hyperlipidemia, diabetes, and arteriosclerosis), enhancement of physiological function (e.g., hyperglycemia, insulin resistance, and lipid metabolism promotion) and endurance, and prevention or improvement of fatigue.
  • When the agents of the present invention are used as pharmaceutical drugs, they can be made into oral solid preparations such as tablets and granules and into oral liquid preparations such as internal-use liquid medicines and syrups.
  • When the oral solid preparations are prepared, nootkatone of the present invention can be supplemented appropriately with pharmaceutically acceptable carriers, for example excipients, if necessary, binders, disintegrants, lubricants, coloring agents, flavoring agents, and odor-improving agents, to produce tablets, coated tablets, granules, powders, capsules, and so on by routine methods. When the oral liquid preparations are prepared, nootkatone of the present invention can be supplemented with flavoring agents, buffers, stabilizers, and so onto produce internal-use liquid medicines, syrups, elixirs, and so on by routine methods.
  • The amount of nootkatone mixed into the food, drink, pharmaceutical drug, pet food, and so on differs depending on its usage pattern and is usually 0.0002 to 5% by mass, preferably 0.001 to 3% by mass, more preferably 0.02 to 2% by mass when nootkatone is used in the foods, drinks, and pet foods. The amount of nootkatone used in a pharmaceutical drug, for example an oral solid preparation such as tablets, granules, capsules or an oral liquid preparation such as internal-use liquid medicines and syrups is usually 0.01 to 95% by mass, preferably 0.1 to 95% by mass, more preferably 2 to 80% by mass.
  • The doses (effective intakes) of the AMPK activating agent, lipid metabolism activating agent, antiobesity agent, antidiabetic agent, antiarteriosclerotic agent, antihyperlipidemic agent, and exercise-substituting agent of the present invention are preferably 1 to 2000 mg/60 kg of body weight per day, more preferably 1 to 1000 mg/60 kg of body weight per day, even more preferably 2 to 1000 mg/60 kg of body weight per day, still even more preferably 2 to 700 mg/60 kg of body weight per day, yet still more preferably 5 to 500 mg/60 kg of body weight per day, in terms of the amount of nootkatone.
    • EXAMPLES Example 1
  • A muscle cell line (C2C12) was used to evaluate the AMPK-activating action of nootkatone according to the procedures below with AMPKα and AMPKβ phosphorylation as indexes.
  • Cells of the murine muscle cell line (C2C12) were seeded onto a 25 cm2 flask and cultured in DMEM (+10% FBS, +antimicrobial agent) at 37° C. for 1 to 2 days. When the cells became confluent, the culture solution was removed, and the cells were washed with PBS (−) and further cultured for 7 to 8 days in fresh DMEM (2% (V/V) horse serum), which was in turn replaced by a fresh culture solution every 2 to 3 days. The culture solution was then removed, and the cells were washed with PBS (−) and further cultured in fresh DMEM (−FBS) for 1 day. After the removal of the culture solution, the cells were cultured in DMEM (−FBS) containing a predetermined concentration of nootkatone (obtained from Wako Pure Chemical Industries, Ltd.) for 60 minutes. After the culture solution was subsequently removed and the cells were washed with PBS (−), 200 μL of cell lysis solution (10 mmol/L Tris (pH 7.4), 50 mmol/L sodium chloride, 30 mmol/L sodium pyrophosphate, 0.5% (V/V) Triton X-100, protease inhibitor cocktail (SIGMA P2714), phosphatase inhibitor cocktail-1 (SIGMA P2850), phosphatase inhibitor cocktail-2 (SIGMA P5726)) was added and the cell lysis solution was collected with a cell scraper. The collected cell lysis solution was well homogenized by passing it through a syringe with a 23G needle three times and then left on ice for 30 minutes. The homogenate was centrifuged at 15000 r/min at 4° C. for 15 minutes, and the resulting supernatant protein was used in the measurement below.
  • The concentration of the supernatant protein was measured, and the protein concentrations were then adjusted among samples to constant concentrations. To each of the samples, SDS buffer (250 mmol/L Tris, 12.5% by mass of SDS, 20% by mass of glycerin) in a 1/4 volume thereof and further 2-mercaptoethanol and bromophenol blue were added. The resulting mixtures were thermally denatured at 95° C. and rapidly cooled at 4° C. to prepare samples for electrophoresis.
  • Predetermined amounts (approximately 20 to 40 μg) of the samples for electrophoresis were subjected to SDS-PAGE (12% gel) and transferred to a membrane. Then, phospho-AMPKα and phospho-AMPKβ were detected by using anti-phospho-AMPKα (Thr72) antibodies (manufactured by Cell Signaling Technology, Inc.) or anti-phospho-AMPKβ (Ser108) antibodies (manufactured by Cell Signaling Technology, Inc.) as primary antibodies, anti-rabbit-HRP antibodies (manufactured by Amersham Biosciences) as secondary antibodies, and Phototope-HRP Western Detection System (manufactured by Cell Signaling Technology, Inc.) as a detection reagent. The degree of AMPK activation was indicated as a relative value to that of a control (sample-free group) defined as 100 by digitizing (pixelizing) detected band strength by image analysis (EDAS290 image analysis system; KODAK).
    TABLE 1
    Nootkatone
    (μmol/L)
    Control 50 100 150
    Phospho- 100 402 952 1077
    AMPKα
    Phospho- 100 241 314  358
    AMPKβ
  • As can be seen from Table 1, nootkatone has a strong AMPK-activating action in the muscle cells.
    • Example 2 Effect of Nootkatone
  • The antiobesity, antidiabetic, and antilifestyle-related disease effects of nootkatone were evaluated as described below.
  • Seven-week-old C57BL/6 male mice were divided into 3 groups each containing 10 mice and raised with each diet of the composition described in Table 2.
    TABLE 2
    (%) Group 1 Group 2 Group 3
    Plant oil 5 25 25
    Lard 0 5 5
    Sucrose 0 13 13
    Casein 20 20 20
    Potato starch 66.5 28.5 28
    Vitamin 1 1 1
    Mineral 3.5 3.5 3.5
    Cellulose 4 4 4
    Nootkatone 0 0 0.5
  • Twenty-two weeks later, their body weights were measured, while blood was collected from the mice under ether anesthesia and under non-fasting conditions to measure serum glucose, cholesterol, triglyceride, insulin, and leptin levels. The amount of visceral fat (epididymal fat, retroperitoneal fat, and perirenal fat) was also measured. The result is shown in Table 3.
    TABLE 3
    Group 1 Group 2 Group 3
    Body weight (g) 33.2 40.3 30.4
    Epididymal fat (g) 0.89 1.91 0.47
    Retroperitoneal fat (g) 0.27 0.55 0.15
    Perirenal fat (g) 0.15 0.38 0.07
  • A remarkable rise in body weight and an increase in the amount of visceral fat were observed in Group 2 as compared with Group 1, whereas an increment of body weights and the amount of visceral fat were remarkably reduced in Group 3 as compared with Group 2. Namely, nootkatone of the present invention was shown to have excellent antiobesity effect. The result of blood analysis is shown in Table 4.
    TABLE 4
    Group 1 Group 2 Group 3
    Total cholesterol (mg/dL) 137.9 169.4 131.3
    Triglyceride (mg/dL) 70.9 95.7 54.3
    Glucose (mg/dL) 214.1 240.6 212.3
    Leptin (ng/mL) 16.6 33.3 6.2
    Insulin (ng/mL) 2.56 3.87 1.26
  • A remarkable rise in blood-sugar level (glucose) was observed in Group 2 as compared with Group 1, whereas a rise in blood-glucose level was not observed in Group 3 as compared with Group 1. The blood-glucose level was also low in Group 2. Nootkatone of the present invention had excellent inhibitory effect on a rise in blood-glucose level and was therefore considered to be effective for controlling diabetes.
  • A remarkable rise in cholesterol level was observed in Group 2 as compared with Group 1, whereas a rise in the cholesterol level was low in Group 3 as compared with Group 1. The cholesterol level was also low in Group 2. Nootkatone of the present invention had excellent inhibitory effect on a rise in blood cholesterol level and was therefore considered to be effective for inhibiting arteriosclerosis.
  • A remarkable rise in triglyceride level was observed in Group 2 as compared with Group 1, whereas a rise in the triglyceride level was low in Group 3 as compared with Group 1. The triglyceride level was also low in Group 2. Nootkatone of the present invention had excellent inhibitory effect on a rise in blood triglyceride level and was therefore considered to be effective for controlling hyperlipidemia.
  • A remarkable rise in insulin level was observed in Group 2 as compared with Group 1, whereas a rise in the insulin level was low in Group 3 as compared with Group 1. The insulin level was also low in Group 2. Nootkatone of the present invention had excellent inhibitory effect on a rise in blood insulin level and was therefore considered to be effective for controlling hyperinsulinemia. Moreover, this result shows that nootkatone inhibits the onset of Type 2 diabetes with insulin resistance.
  • A remarkable rise in leptin level was observed in Group 2 as compared with Group 1, whereas a rise in leptin level was low in Group 3 as compared with Group 1. The leptin level was also low in Group 2. Nootkatone of the present invention had excellent inhibitory effect on a rise in blood leptin level and was therefore considered to be effective for controlling hyperleptinemia.
    • Example 3 Lipid Metabolism-Activating Effect
  • Seven-week-old Balb/c male mice were divided into 2 groups, to which a physiological saline (control) or nootkatone at 200 mg/kg of body weight was then orally administered for 10 consecutive days. Then, their livers and skeletal muscles (gastrocnemius muscle+soleus muscle) were collected. The livers and skeletal muscles were respectively homogenized in a buffer (250 mM sucrose, 1 mM EDTA in 10 mM HEPES (pH 7.2)), and the insoluble tissue residues were removed by centrifugation to obtain supernatants. The obtained supernatants were measured for protein levels. The protein levels were adjusted among samples to constant levels, and the samples were used in the measurement of lipid metabolism activity (β-oxidation activity). A 100-μg aliquot of the supernatant protein was reacted at 37° C. for 20 minutes with 0.1 μCi [14C]-palmitic acid in a buffer (50 mM Tris-HCl (pH 8.0), 40 mM NaCl, 2 mM KCl, 2 mM MgCl2, 1 mM DTT, 5 mM ATP, 0.2 mM L-carnitine, 0.2 mM NAD, 0.06 mM FAD, 0.12 mM CoA, 3 mM α-cyclodextrin) at the final volume of 200 μL. The reaction was terminated with 200 μL of 0.6 N perchloric acid, and the unreacted [14C]-palmitic acid was removed 3 times with 1 mL hexane. Lipid-degrading activity was measured by measuring radioactivity of the aqueous layer.
  • The measurement result is shown in Table 5. The degree of the lipid-degrading activity was indicated as a relative value to that of the control defined as 100. The lipid-degrading activity (β-oxidation activity) of the liver and skeletal muscle remarkably increased in the mice fed with nootkatone. Thus, nootkatone was shown to be effective for activating lipid metabolism. Nootkatone also improved a variety of the symptoms partly caused by lack of exercise via its AMPK-activating action and was therefore shown to be useful as an exercise-substituting agent having effect similar to that of exercise, particularly an exercise-substituting agent intended for the prevention and improvement of obesity, body fat accumulation, diabetes, fatty liver, lifestyle-related disease, and the like.
    TABLE 5
    Control Nootkatone
    Liver 100 273
    Skeletal muscle 100 271
    • Example 4 Evaluation of Endurance-Enhancing and Antifatigue Effects of Nootkatone
  • The endurance-enhancing and antifatigue effects of nootkatone were evaluated as described below. Nootkatone used was a product of Avocado.
  • The endurance-enhancing and antifatigue effects were evaluated according to the measurement method of maximum swimming time of mice (Reference: Am J Physiol Regul Integr Comp Physiol, Vol. 288, R708-R715, 2005) in a current water pool. The experimental pool used was a clear acrylic pool (90 cm long×45 cm wide×45 cm deep) filled to a depth of 38 cm with water maintained at 34° C. with a heater. The current in the pool was generated with a pump (C-P60H, manufactured by Hitachi), and the current speed was adjusted by connecting Water flowmeter (Tofco) to the pump and opening and closing a valve. The current speed was measured with a digital current meter (SV-101-25S, Sankou Seimitsu Kogyo).
  • Experimental animals used were 5-week-old Balb/c male mice (Charles River Laboratories, Inc.). The mice were preliminarily raised for 1 week under a constant raising environment (23±2° C., light period: 7 a.m. to 7 p.m.) and acclimated. In subsequent 1-week training, the mice were accustomed to swimming exercise three times a week (subjected to swimming exercise for 30 minutes at a current speed of 5 L/min on the first day, and for 30 minutes at a current speed of 6 L/min on the third and fifth days). For the next one week, the maximum swimming time of each of the individuals fasted for 2 hours was measured twice at a current speed of 7 L/min (maximum swimming time was set to the point in time when the mouse failed to rise to the surface of the water to breathe and was rescued). The mice were divided into 2 groups, a test diet group and a control diet group, each containing 8 mice, to prevent a difference in maximum swimming time between the groups. Diets prepared in the formulation composition shown in Table 8 were used to raise the mice for 10 weeks. During this period, the measurement of maximum swimming time (7 L/min) and training (6 L/min, 30 minutes) were performed once every week. The maximum swimming times of the mice on the 10th week of raising are shown in Table 7.
    TABLE 6
    Composition of diet (% by mass)
    Control diet Test diet
    Lipid (%) 10 10
    Casein (%) 20 20
    Potato starch (%) 55.5 55.3
    Cellulose (%) 8.1 8.1
    Vitamin (%) 2.2 2.2
    Methionine (%) 0.2 0.2
    Mineral (%) 4 4
    Nootkatone (%) 0 0.2
    Total (%) 100 100
  • TABLE 7
    Maximum swimming time before and after 10-week raising
    Before raising After 10 week
    Maximum Statistically Maximum Statistically
    swimming time significant swimming time significant
    (min) difference (min) difference
    Control 27.32 ± 1.39 31.08 ± 2.34
    diet
    Test 27.31 ± 1.72 N.S 40.01 ± 3.17 P < 0.05
    diet

    *Statistically significant difference is relative to the control group (t-test)
  • As can be seen from Table 7, the maximum swimming time after 10-week raising is significantly prolonged in the mice fed with the test diet containing nootkatone as compared with the control diet group, and nootkatone has endurance-enhancing and antifatigue effects.
    • Example 5 Preparation Examples
  • A variety of preparations described in (1) to (21) below were manufactured.
  • (1) Capsule for Prevention or Improvement of Lifestyle-Related diseases
  • Compositions (300 mg) described below were encapsulated into an encapsulating agent.
    TABLE 8
    Nootkatone 50% by weight
    Corn starch 20
    Cellulose 18
    Tocopherol 2
    Lactose 10

    (2) Tablet for Prevention or Improvement of Lifestyle-Related Diseases
  • Compositions (1 tablet=250 mg) described below were tableted to produce a tablet.
    TABLE 9
    Nootkatone 20% by weight
    Corn starch 20
    Cellulose 20
    Vitamin C 20
    Lactose 20
  • (3) Granule for prevention or improvement of lifestyle-related diseases Compositions (1 bag=500 mg) described below were mixed to produce a granule.
    TABLE 10
    Nootkatone 25% by weight
    Fructose 30
    Glucose 30
    Skimmed milk powder 10
    Caffeine 5

    (4) Drink for Prevention or Improvement of Obesity or Lifestyle-Related Disease
  • Compositions described below were mixed to produce a fruit juice drink.
    TABLE 11
    Nootkatone 100 mg
    Grapefruit juice 500 mL

    (5) Drink for Prevention or Improvement of Obesity or Lifestyle-Related Disease
  • Compositions described below were mixed to produce a fruit juice drink.
    TABLE 12
    Nootkatone 50 mg
    Vitamin C 300 mg
    Orange juice 300 mL
    Water 200 mL
    Flavor Certain quantity
    Isomerized sugar 5 g

    (6) Drink for Prevention or Improvement of Obesity or
  • Lifestyle-Related Disease Compositions described below were mixed to produce a tea drink.
    TABLE 13
    Nootkatone 20 mg
    Tea catechin 200 mg
    Vitamin C 500 mg
    Green tea 500 mL

    (7) Drink for Prevention or Improvement of Obesity or Lifestyle-Related Disease
  • Compositions described below were mixed to produce a sports drink.
    TABLE 14
    Water 500 mL
    Nootkatone 60 mg
    Fructose 3 g
    Glucose 2 g
    Vitamin C 500 mg
    Citric acid 100 mg
    Sodium citrate 2 g
    Flavor Certain quantity
    Malic acid 200 mg

    (8) Exercise-Substituting Functional Drink
  • A carbonated drink of the composition below was produced.
    TABLE 15
    Nootkatone 50 mg
    Vitamin C 500 mg
    Carbonated water 495 mL
    Lemon juice 5 mL
    Flavor Certain quantity
    Aspartame 5 g

    (9) Exercise-Substituting Functional Drink
  • A carbonated drink of the composition below was produced.
    TABLE 16
    Nootkatone 100 mg
    Vitamin C 500 mg
    Carbonated water 500 mL
    Lemon juice 5 mL
    Flavor Certain quantity
    Aspartame 5 g

    (10) Exercise-Substituting Functional Food
  • Compositions (1 tablet=1000 mg) described below were tableted to produce a chewable tablet food.
    TABLE 17
    Nootkatone 2.5% by mass
    Maltose 11
    Lactose 30
    Glucose 15
    Vitamin C 20
    Vitamin E 1
    Cellulose 10
    Xylitol 10
    Flavor 0.5

    (11) Exercise-Substituting Functional Drink
  • A carbonated drink of the composition below was produced.
    TABLE 18
    Nootkatone 10 mg
    Vitamin C 500 mg
    Carbonated water 500 mL
    Lemon juice 5 mL
    Flavor Certain quantity
    Aspartame 5 g

    (12) Drink for Prevention or Improvement of Obesity or Lifestyle-Related Diseases
  • Compositions described below were mixed to produce a drink.
    TABLE 19
    Water 350 mL
    Nootkatone 5 mg
    Fructose 3 g
    Glucose 2 g
    Vitamin C 750 mg
    Citric acid 100 mg
    Sodium citrate 1.5 g
    Flavor Certain quantity
    Malic acid 150 mg

    (13) Drink for Prevention or Improvement of Obesity or Lifestyle-Related Diseases
  • Compositions described below were mixed to produce a fruit juice drink.
    TABLE 20
    Nootkatone 4 mg
    Vitamin C 300 mg
    Orange juice 300 mL
    Water 200 mL
    Flavor Certain quantity
    Isomerized sugar 5 g

    (14) Tablet for Prevention or Improvement of Lifestyle-Related Diseases
  • Compositions (1 tablet=250 mg) described below were tableted to produce a tablet.
    TABLE 21
    Nootkatone 5% by weight
    Corn starch 35
    Cellulose 20
    Vitamin C 20
    Lactose 20

    (15) Drink for Endurance Enhancement or Antifatigue
  • Compositions described below were mixed to produce a fruit juice drink.
    TABLE 22
    Nootkatone 5 mg
    Vitamin C 300 mg
    Grapefruit juice 400 mL
    Water 100 mL
    Flavor Certain quantity
    Glucose 2 g

    (16) Capsule for Endurance Enhancement or Antifatigue
  • Compositions (300 mg) described below were encapsulated into an encapsulating agent.
    TABLE 23
    Nootkatone 5% by mass
    Vitamin C 20
    Cellulose 10
    Corn starch 40
    Tocopherol 2
    Lactose 23

    (17) Tablet for Endurance Enhancement or Antifatigue
  • Compositions (1 tablet=250 mg) described below were tableted to produce a tablet.
    TABLE 24
    Nootkatone 10% by mass
    Corn starch 50
    Cellulose 10
    Lactose 30

    (18) Granule for Endurance Enhancement or Antifatigue
  • Compositions (1 bag=500 mg) described below were mixed to produce a granule.
    TABLE 25
    Nootkatone 1% by mass
    Corn starch 20
    Fructose 30
    Glucose 25
    Skimmed milk powder 14
    Caffeine 10

    (19) Food for endurance enhancement or antifatigue
  • Compositions (1 tablet=1000 mg) described below were tableted to produce a chewable tablet food.
    TABLE 26
    Nootkatone 1% by mass
    Lactose 15
    Maltose 15
    Glucose 20
    Glutamine 10
    Vitamin C 15
    Cellulose 10
    Caffeine 4
    Xylitol 8
    Vitamin E 1
    Flavor 1

    (20) Drink for Endurance Enhancement or Antifatigue
  • Compositions described below were mixed to produce a drink for endurance enhancement or antifatigue.
    TABLE 27
    Water 500 mL
    Nootkatone 10 mg
    Fructose 3 g
    Glucose 2 g
    Vitamin C 500 mg
    Sodium citrate 2 g
    Malic acid 100 mg
    Caffeine 50 mg
    Flavor Certain quantity

    (21) Capsule for Endurance Enhancement or Antifatigue
  • Compositions (300 mg) described below were encapsulated into an encapsulating agent.
    TABLE 28
    Nootkatone 10% by mass
    Vitamin C 20
    Cellulose 10
    Corn starch 45
    Tocopherol 2
    Lactose 13

Claims (14)

1. An AMPK activating agent comprising nootkatone as an active ingredient.
2. A lipid metabolism activating agent comprising nootkatone as an active ingredient.
3. An antiobesity agent comprising nootkatone as an active ingredient.
4. An antidiabetic agent comprising nootkatone as an active ingredient.
5. An antiarteriosclerotic agent comprising nootkatone as an active ingredient.
6. An antihyperlipidemic agent comprising nootkatone as an active ingredient.
7. An exercise-substituting agent comprising nootkatone as an active ingredient.
8. An endurance enhancing agent comprising nootkatone as an active ingredient.
9. An antifatigue agent comprising nootkatone as an active ingredient.
10. A method for activating AMPK comprising administering nootkatone in an effective amount.
11. A method for preventing, treating and/or improving lifestyle-related disease, comprising administering nootkatone in an effective amount.
12. The method according to claim 11, wherein the lifestyle-related disease is selected from obesity, hyperlipidemia, diabetes, and arteriosclerosis.
13. A method for substituting exercise comprising administering nootkatone in an effective amount.
14. A method for enhancing endurance and/or for removing fatigue comprising administering nootkatone in an effective amount.
US11/480,504 2005-09-05 2006-07-05 AMPK activating agent Abandoned US20070054965A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/008,086 US8829057B2 (en) 2005-09-05 2011-01-18 AMPK activating agent

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005-257047 2005-09-05
JP2005257047A JP4745764B2 (en) 2004-09-09 2005-09-05 AMPK activator
JP2005-338405 2005-11-24
JP2005338405A JP4719556B2 (en) 2005-11-24 2005-11-24 Endurance improver

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/008,086 Division US8829057B2 (en) 2005-09-05 2011-01-18 AMPK activating agent

Publications (1)

Publication Number Publication Date
US20070054965A1 true US20070054965A1 (en) 2007-03-08

Family

ID=37830790

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/480,504 Abandoned US20070054965A1 (en) 2005-09-05 2006-07-05 AMPK activating agent
US13/008,086 Active US8829057B2 (en) 2005-09-05 2011-01-18 AMPK activating agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/008,086 Active US8829057B2 (en) 2005-09-05 2011-01-18 AMPK activating agent

Country Status (1)

Country Link
US (2) US20070054965A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009031044A3 (en) * 2007-04-27 2009-09-17 Genexel-Sein, Inc. Ampk deficient animals, screening methods, and related therapeutics and diagnostics
US20110112047A1 (en) * 2006-12-29 2011-05-12 Evans Ronald M Methods for enhancing muscle performance and tone
WO2012094173A1 (en) 2011-01-06 2012-07-12 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring ampk activation
US20120225139A1 (en) * 2009-11-09 2012-09-06 Bio-Engineered Supplements & Nutrition, Inc. Method and Composition for Improved Anabolism
KR101218458B1 (en) * 2010-08-06 2013-01-04 동국대학교 경주캠퍼스 산학협력단 Composition for Prevention or Treatment of Circulatory Disorder Comprising the Nootkatone
EP2408434A4 (en) * 2009-03-16 2013-11-27 Ipintl Llc TREATMENT OF ALZHEIMER'S DISEASE AND OSTEOPOROSIS AND REDUCTION OF AGING

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289865B (en) * 2016-05-26 2021-02-23 中国热带农业科学院热带生物技术研究所 Application of nootkatone
CN111658623A (en) * 2020-07-30 2020-09-15 海南医学院 Application of grapefruit ketone in the prevention and treatment of non-alcoholic fatty liver disease
JP2025520696A (en) * 2022-06-24 2025-07-03 ニコベンチャーズ トレーディング リミテッド Oral Compositions Containing Receptor Modulators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562087A (en) * 1984-06-11 1985-12-31 Squirt & Company Grapefruit juice and process for preparing same
US20030026811A1 (en) * 2001-07-26 2003-02-06 Shin Hirayama Health food and preparation having an anti-obesity effect
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
US20050084548A1 (en) * 2002-02-28 2005-04-21 San-Ei Gen F.F.I., Inc Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient
US20050175764A1 (en) * 2002-05-17 2005-08-11 Kinya Takagaki Food composition for enhancing endurance

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3282840B2 (en) 1991-10-30 2002-05-20 東洋製薬株式会社 Composition for improving long-distance running ability
JPH0847381A (en) 1994-08-08 1996-02-20 Meiji Seika Kaisha Ltd Food or beverage for improving durability
JP2002186424A (en) 2000-10-12 2002-07-02 Kanegafuchi Chem Ind Co Ltd Food/drink containing conjugated trienoic acid-based oil and fat
JP2005047935A (en) 2000-12-25 2005-02-24 Shiseido Co Ltd Slimming composition
JP2002193824A (en) 2000-12-25 2002-07-10 Shiseido Co Ltd Sympathetic nervous system-activating perfume composition and anti-obesity perfume composition characterized by containing grape fruit oil
JP3877537B2 (en) 2001-03-07 2007-02-07 高砂香料工業株式会社 Antibacterial agent for oral composition and oral composition containing the same
JP4199448B2 (en) 2001-10-30 2008-12-17 琉球セメント株式会社 Pharmaceutical agent comprising sugarcane polyphenol-containing substance as active ingredient and use thereof
JP2003261445A (en) 2002-03-05 2003-09-16 Nippon Beet Sugar Mfg Co Ltd Blood neutral fat reducing agent
JP2003286180A (en) 2002-03-28 2003-10-07 Fuji Oil Co Ltd Obesity suppressant and food containing it
JP2005089384A (en) 2003-09-18 2005-04-07 Kao Corp Endurance improver
JP2005097161A (en) 2003-09-24 2005-04-14 Nisshin Pharma Inc Anti-fatigue composition and food containing the same
JP2005097162A (en) 2003-09-24 2005-04-14 Nisshin Pharma Inc Anti-fatigue composition containing glutamine peptide
JP2005137204A (en) 2003-11-04 2005-06-02 Yutaka Miyauchi Liquid drink
JP2005198642A (en) 2003-12-15 2005-07-28 Yutaka Miyauchi Liquid drinking product using fruit skin of citrus fruit as raw material
JP2005194252A (en) 2004-01-09 2005-07-21 Shiseido Co Ltd Fat accumulation-suppressing composition
JP2005272401A (en) 2004-03-25 2005-10-06 Tendou Seiyaku Kk Chewable tablet
WO2006001278A1 (en) 2004-06-28 2006-01-05 Kao Corporation Ampk activator
JP4622625B2 (en) * 2005-03-29 2011-02-02 Ｊｆｅスチール株式会社 Cold rolling method for metal sheet
JP5123135B2 (en) 2008-10-17 2013-01-16 パナソニック株式会社 Massage equipment

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562087A (en) * 1984-06-11 1985-12-31 Squirt & Company Grapefruit juice and process for preparing same
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
US20050003976A1 (en) * 2000-12-25 2005-01-06 Shiseido Company, Ltd. Sympathetic nerve-stimulating fragrant compositions
US20050158264A1 (en) * 2000-12-25 2005-07-21 Shiseido Company, Ltd. Sympathetic nerve-stimulating fragrant compositions
US20030026811A1 (en) * 2001-07-26 2003-02-06 Shin Hirayama Health food and preparation having an anti-obesity effect
US20050084548A1 (en) * 2002-02-28 2005-04-21 San-Ei Gen F.F.I., Inc Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient
US20050175764A1 (en) * 2002-05-17 2005-08-11 Kinya Takagaki Food composition for enhancing endurance

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110112047A1 (en) * 2006-12-29 2011-05-12 Evans Ronald M Methods for enhancing muscle performance and tone
US9192601B2 (en) * 2006-12-29 2015-11-24 Salk Institute For Biological Studies Methods for enhancing muscle performance and tone
WO2009031044A3 (en) * 2007-04-27 2009-09-17 Genexel-Sein, Inc. Ampk deficient animals, screening methods, and related therapeutics and diagnostics
EP2408434A4 (en) * 2009-03-16 2013-11-27 Ipintl Llc TREATMENT OF ALZHEIMER'S DISEASE AND OSTEOPOROSIS AND REDUCTION OF AGING
US20120225139A1 (en) * 2009-11-09 2012-09-06 Bio-Engineered Supplements & Nutrition, Inc. Method and Composition for Improved Anabolism
US8491943B2 (en) * 2009-11-09 2013-07-23 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
KR101218458B1 (en) * 2010-08-06 2013-01-04 동국대학교 경주캠퍼스 산학협력단 Composition for Prevention or Treatment of Circulatory Disorder Comprising the Nootkatone
WO2012094173A1 (en) 2011-01-06 2012-07-12 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring ampk activation

Also Published As

Publication number Publication date
US20110118359A1 (en) 2011-05-19
US8829057B2 (en) 2014-09-09

Similar Documents

Publication Publication Date Title
US8829057B2 (en) AMPK activating agent
US5932624A (en) Vitamin supplement composition
US20110319497A1 (en) Ampk activator
US8507547B2 (en) Anti-fatigue agents and oral compositions containing andrographolide as active ingredient
US10485836B2 (en) Anti-fatigue composition used for increasing endurance performance, and use of the same
US12048683B2 (en) Kaempferol analog-containing composition
KR20090082908A (en) Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses
JP2019513382A (en) Composition for the prevention, amelioration or treatment of hyperuricemia or hyperuricemia-related metabolic disorders, which comprises the extract of Yuchichi as an active ingredient
WO2007010976A1 (en) Body weight gain inhibitory composition comprising d-psicose and use thereof
KR101266889B1 (en) Functional food compositions having the recovery effect of blood composition and function
JP2014198684A (en) Blood sugar metabolism improver
EP3991728A1 (en) Hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin
JP6879297B2 (en) Composition for suppressing or ameliorating physical dysfunction or dysfunction associated with aging, or mental dysfunction or dysfunction associated with aging
KR101660834B1 (en) Anti-diabetic effects of Gypenoside 75
KR20140104090A (en) A pharmaceutical composition for treating and preventing fatty liver diseases containing curcumin as an active ingredient
US20160184248A1 (en) Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response
US20050267055A1 (en) Agent for improvement of glucose tolerance
JP6842308B2 (en) Nocturnal postprandial blood glucose elevation inhibitor
JP7724290B2 (en) Composition for reducing endoplasmic reticulum stress
US6599522B2 (en) Triglyceride reducing agent
JP2008543903A (en) Compounds for the treatment of non-autoimmune type 2 diabetes and / or syndrome X
US20070092587A1 (en) Extract from plant of japanese parsley family and process for producing the same
KR101572311B1 (en) A composition for preventing or treating obesity comprising 2-amino-2-norbornanecarboxylic acid
US20170209511A1 (en) Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients
RU2505290C2 (en) Pharmaceutical composition possessing exhibiting property of endothelial dysfunction reduction accompanying cardiovascular diseases

Legal Events

Date Code Title Description
AS Assignment

Owner name: KAO CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MURASE, TAKATOSHI;MINEGISHI, YOSHIHIKO;REEL/FRAME:018365/0534

Effective date: 20060810

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION